Before
The therapy was used outside its original approval in patients with a left ventricular assist device (LVAD), in a particularly sensitive clinical setting. The Notified Body required additional evidence on safety and performance under the MDR. Real-world data was lacking, and the risk of a regulatory objection was high.





